8 Analysts Have This To Say About Integra Lifesciences
8 Analysts Have This To Say About Integra Lifesciences
8位分析師就英特格拉生命科學發表看法
In the last three months, 8 analysts have published ratings on Integra Lifesciences (NASDAQ:IART), offering a diverse range of perspectives from bullish to bearish.
在過去的三個月中，有8位分析師公佈了對Integra Lifesciences（納斯達克股票代碼：IART）的評級，提供了從看漲到看跌的不同視角。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表簡要介紹了他們最近的收視率，展示了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $28.12, a high estimate of $40.00, and a low estimate of $24.00. A decline of 21.34% from the prior average price target is evident in the current average.
分析師評估的12個月目標股價揭示了進一步的見解，平均目標價爲28.12美元，最高估計爲40.00美元，低估值爲24.00美元。目前的平均價格比先前的平均目標股價下降了21.34％。
Diving into Analyst Ratings: An In-Depth Exploration
深入分析師評級：深度探索
An in-depth...
對分析...
登入免費觀看全文
登入/註冊